MRZM (MRZM) Stock Price & Analysis
MRZM (MRZM) rose 0.00% to USD 0 as of June 13, 2026 at 13:08 UTC, according to Nexqual real-time market data.
MRZM last closed at USD 0; the session ranged USD 0.01–0.01 on volume of 1,970 shares. Market capitalization is $39,537, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, June 13, 2026 at 13:08 UTC.
Key Statistics (as of June 13, 2026 at 13:08 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 1,970 shares |
| Market Cap | $39,537 |
| Exchange | PNK |
Technical Analysis (MRZM)
Nexqual's technical model rates MRZM "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 13, 2026 at 13:08 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (MRZM)
Wall Street analysts rate MRZM "None", per Nexqual as of June 13, 2026 at 13:08 UTC.
| Consensus Rating | None |
|---|
Earnings (MRZM)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2011-09-30 | USD -2.23 vs est -1.45 ▼ miss |
| 2011-06-30 | USD -2.23 vs est -0.87 ▼ miss |
Source: Nexqual, June 13, 2026 at 13:08 UTC.
Financials & Fundamentals (MRZM)
| Total Revenue | $183,417 |
|---|---|
| Gross Margin | +63.27% |
| Operating Margin | -6741.22% |
| Profit Margin | +0.00% |
| Current Ratio | 0.03 |
| Total Cash | $63,732 |
| Total Debt | $26.66M |
| Free Cash Flow | $-44.98M |
Source: Nexqual, June 13, 2026 at 13:08 UTC.
Financial Health Score (MRZM)
Nexqual rates MRZM's overall financial health "Weak" across five dimensions, as of June 13, 2026 at 13:08 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $64K cash vs $27M debt |
| Cash Flow | Weak — FCF negative: -$45M, burning cash |
| Efficiency | Mixed — No data |
Ownership (MRZM)
| Insider Ownership | +34.96% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 131.79M |
| Float | 85.64M |
Source: Nexqual, June 13, 2026 at 13:08 UTC.
Leadership (MRZM)
MRZM is led by David L. Barthel (age 67), CEO, Secretary & Director, per Nexqual as of June 13, 2026 at 13:08 UTC.
| CEO, Secretary & Director | David L. Barthel (age 67) |
|---|---|
| CFO, Treasurer & Director | George Kovalyov C.A. (age 40) |
| Executive VP & Chief Scientific Officer | Catherine J. Pachuk (age 68) |
| Vice President of Finance | Harrison Albert Ross C.F.A. (age 32) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EMMA | Emmaus Life Sciences, Inc. | USD 0.01 | ▼ 9.09% |
| ACBM | ACRO BIOMEDICAL CO LTD | USD 0.03 | ▲ 0% |
| PBSV | Pharma-Bio Serv, Inc. | USD 0.57 | ▲ 16.33% |
| CLCS | Cell Source, Inc. | USD 0.82 | ▲ 0% |
| MBXBF | MICROBIX BIOSYSTEMS | USD 0.19 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 13, 2026 at 13:08 UTC. This page is informational and not investment advice.